Dataset Information


Effect of Granulocyte-Macrophage Colony-Stimulating Factor With or Without Supervised Exercise on Walking Performance in Patients With Peripheral Artery Disease: The PROPEL Randomized Clinical Trial.

ABSTRACT: Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improving walking ability in people with lower extremity peripheral artery disease (PAD) are unclear. Walking exercise may augment the effects of GM-CSF in PAD, since exercise-induced ischemia enhances progenitor cell release and may promote progenitor cell homing to ischemic calf muscle.To determine whether GM-CSF combined with supervised treadmill exercise improves 6-minute walk distance, compared with exercise alone and compared with GM-CSF alone; to determine whether GM-CSF alone improves 6-minute walk more than placebo and whether exercise improves 6-minute walk more than an attention control intervention.Randomized clinical trial with 2?×?2 factorial design. Participants were identified from the Chicago metropolitan area and randomized between January 6, 2012, and December 22, 2016, to 1 of 4 groups: supervised exercise?+?GM-CSF (exercise?+?GM-CSF) (n?=?53), supervised exercise?+?placebo (exercise alone) (n?=?53), attention control??+?GM-CSF (GM-CSF alone) (n?=?53), attention control?+?placebo (n?=?51). The final follow-up visit was on August 15, 2017.Supervised exercise consisted of treadmill exercise 3 times weekly for 6 months. The attention control consisted of weekly educational lectures by clinicians for 6 months. GM-CSF (250 ?g/m2/d) or placebo were administered subcutaneously (double-blinded) 3 times/wk for the first 2 weeks of the intervention.The primary outcome was change in 6-minute walk distance at 12-week follow-up (minimum clinically important difference, 20 m). P values were adjusted based on the Hochberg step-up method.Of 827 persons evaluated, 210 participants with PAD were randomized (mean age, 67.0 [SD, 8.6] years; 141 [67%] black, 82 [39%] women). One hundred ninety-five (93%) completed 12-week follow-up. At 12-week follow-up, exercise?+?GM-CSF did not significantly improve 6-minute walk distance more than exercise alone (mean difference, -6.3 m [95% CI, -30.2 to +17.6]; P?=?.61) or more than GM-CSF alone (mean difference, +28.7 m [95% CI, +5.1 to +52.3]; Hochberg-adjusted P?=?.052). GM-CSF alone did not improve 6-minute walk more than attention control?+?placebo (mean difference, -1.4 m [95% CI, -25.2 to +22.4]; P?=?.91). Exercise alone improved 6-minute walk compared with attention control?+?placebo (mean difference, +33.6 m [95% CI, +9.4 to +57.7]; Hochberg-adjusted P?=?.02).Among patients with PAD, supervised treadmill exercise significantly improved 6-minute walk distance compared with attention control?+?placebo, whereas GM-CSF did not significantly improve walking performance, either when used alone or when combined with supervised treadmill exercise. These results confirm the benefits of exercise but do not support using GM-CSF to treat walking impairment in patients with PAD.clinicaltrials.gov Identifier: NCT01408901.


PROVIDER: S-EPMC5820720 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2013-01-01 | S-EPMC3939047 | BioStudies
2019-01-01 | S-EPMC6497365 | BioStudies
2019-01-01 | S-EPMC6405705 | BioStudies
2020-01-01 | S-EPMC7141750 | BioStudies
2009-01-01 | S-EPMC3268032 | BioStudies
2016-01-01 | S-EPMC5220567 | BioStudies
2015-01-01 | S-EPMC4378345 | BioStudies
2013-01-01 | S-EPMC6007977 | BioStudies
2018-01-01 | S-EPMC6202165 | BioStudies
2017-01-01 | S-EPMC5815080 | BioStudies